Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market
RMD's stellar third-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
ResMed: Cornering The Market In Sleep Solutions
ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, enhancing its product portfolio, customer experience, and expanding into new markets, justifying its premium share price. Concerns about GLP-1 drugs reducing ResMed's market are countered by data suggesting increased overall health engagement, boosting interest in sleep health solutions.
ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q3 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Mick Farrell - Chairman & Chief Executive Officer Salli Schwartz - Chief Investor Relations Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Lyanne Harrison - Bank of America Margaret Kaczor - William Blair Davin Thillainathan - Goldman Sachs Anthony Petrone - Mizuho Group David Low - JPMorgan Saul Hadassin - Barrenjoey Dan Hurren - MST Matt Taylor - Jefferies Steve Wheen - Jarden David Bailey - Morgan Stanley Brett Fishbin - KeyBanc Capital Markets Operator Greetings, and welcome to the Q3 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call.
Here's What Key Metrics Tell Us About ResMed (RMD) Q3 Earnings
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
ResMed (RMD) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $2.13 per share a year ago.
ResMed slightly beats quarterly profit estimates on sleep devices demand
Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.
What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why ResMed (RMD) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength?
ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
